1,287 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by AXQ Capital LP

AXQ Capital LP purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,287 shares of the biotechnology company’s stock, valued at approximately $454,000.

Several other institutional investors and hedge funds also recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. bought a new stake in United Therapeutics in the fourth quarter valued at approximately $25,000. Brooklyn Investment Group acquired a new position in shares of United Therapeutics in the 3rd quarter worth approximately $33,000. Millstone Evans Group LLC bought a new stake in shares of United Therapeutics in the 4th quarter valued at $67,000. MassMutual Private Wealth & Trust FSB increased its position in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after buying an additional 58 shares during the period. Finally, Jones Financial Companies Lllp raised its stake in United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after buying an additional 258 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total transaction of $3,710,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nilda Mesa sold 255 shares of the company’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,255 shares of company stock worth $32,614,521 over the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on UTHR. HC Wainwright reaffirmed a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Thursday, February 27th. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 27th. Finally, UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Trading Down 0.2 %

Shares of UTHR stock opened at $312.99 on Friday. The firm has a fifty day simple moving average of $345.10 and a two-hundred day simple moving average of $357.02. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The firm has a market capitalization of $14.06 billion, a PE ratio of 13.75, a price-to-earnings-growth ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The business had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter last year, the firm earned $4.36 EPS. On average, equities analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.